Tiziana Life Sciences (NASDAQ:TLSA) Trading 6.8% Higher – Here’s What Happened
by Mitch Edgeman · The Markets DailyShares of Tiziana Life Sciences Ltd (NASDAQ:TLSA – Get Free Report) shot up 6.8% on Wednesday . The stock traded as high as $1.3060 and last traded at $1.25. 120,896 shares changed hands during trading, a decline of 18% from the average session volume of 147,315 shares. The stock had previously closed at $1.17.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tiziana Life Sciences in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
View Our Latest Research Report on Tiziana Life Sciences
Tiziana Life Sciences Price Performance
The firm’s 50 day simple moving average is $1.39 and its 200-day simple moving average is $1.63.
Institutional Trading of Tiziana Life Sciences
Hedge funds and other institutional investors have recently modified their holdings of the stock. OMERS ADMINISTRATION Corp bought a new stake in Tiziana Life Sciences during the fourth quarter worth about $59,000. Marshall Wace LLP boosted its position in Tiziana Life Sciences by 5.2% during the fourth quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock valued at $420,000 after purchasing an additional 14,005 shares during the last quarter. HRT Financial LP bought a new position in Tiziana Life Sciences in the fourth quarter valued at approximately $36,000. Goldman Sachs Group Inc. grew its stake in Tiziana Life Sciences by 413.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock valued at $164,000 after purchasing an additional 88,830 shares in the last quarter. Finally, Zhang Financial LLC increased its position in shares of Tiziana Life Sciences by 18.6% during the 4th quarter. Zhang Financial LLC now owns 99,900 shares of the company’s stock worth $149,000 after purchasing an additional 15,700 shares during the last quarter.
Tiziana Life Sciences Company Profile
Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.
The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.